Published in Law and Health Weekly, April 15th, 2006
Dr. Charan Behl, Elite's chief scientific officer, discussed the company's two lead opioid products: OxyNal, the company's opioid abuse-resistant oxycodone product and OxyQD, the company's once-daily oxycodone product to address the subject "Unmet Needs in Opioid Therapy."
OxyNal uses a pharmacological agonist-antagonist combination approach of sustained release agonist oxycodone hydrochloride, intended for use in patients with moderate to severe chronic pain, and an antagonist, naltrexone hydrochloride, formulated to deter abusers of the drug.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly